U.S. Health Secretary Robert F. Kennedy Jr. vows to restore the vaccine advisory panel after a judge’s injunction froze its work, aiming to resume critical public health guidance.

The U.S. health secretary, Robert F. Kennedy Jr., announced a concerted effort to restore the operations of the nation’s vaccine advisory panel after a federal judge issued an injunction that froze its decisions and barred it from convening.

Legal block stalls advisory work

Earlier this year, a district court judge halted the panel’s meetings, citing procedural concerns and questioning the legitimacy of some of its recommendations. The ruling effectively silenced the body that provides expert guidance on vaccine policy to the Department of Health and Human Services.

Secretary’s push for a restart

In response, Kennedy has instructed senior officials to file a petition for a stay of the injunction and to seek clarification from the court on the scope of the ruling. The health secretary emphasized that the panel’s expertise is “critical to navigating the current public‑health landscape” and that delays could hamper the rollout of new vaccines and boosters.

Implications for public‑health strategy

The advisory panel, composed of epidemiologists, immunologists and other specialists, has traditionally played a central role in shaping vaccine recommendations, especially amid emerging viral threats. With several clinical trials now underway for promising antiviral drugs, the panel’s input is expected to guide decisions on emergency use authorizations and distribution priorities.

Stakeholder reactions

Public‑health advocates have welcomed the secretary’s move, calling it a “necessary step to ensure science‑based policy.” Conversely, some legal experts caution that any further court action could prolong uncertainty, potentially affecting vaccine confidence and supply chain coordination.

Next steps

The petition is slated for a hearing within the next few weeks. If granted, the panel could reconvene as early as next month, allowing it to resume its advisory duties while the new drug trials progress.

All eyes remain on the court’s decision, as the outcome will shape the federal government’s ability to respond swiftly to the evolving virus outbreak.